Bausch + Lomb Corporation
Health
Performance
2.5
Risk
Sell
Buy
Curious about the Scores? Learn more.

Bausch + Lomb Corporation stock rating and score history

All changes in ratings, performance and outlook tracked over time.

23.08.2026
Slight bounce. Could be noise – or a comeback brewing.
18.08.2026
Respawned at 1 HP. Still fragile, but back in play.
28.07.2026
Calmer waters ahead. Risk signals cooling off.
BLCO
Bausch + Lomb Corporation
18.04
-0.55%
2.5
Sell
Buy
Bausch + Lomb Corporation

Bausch + Lomb Corporation stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Bausch + Lomb Corporation do? Business model and key facts

Get the full picture of Bausch + Lomb Corporation: what it builds, where it operates, and how it makes money.

Bausch + Lomb Corporation Profile

Sector: Healthcare

Industry: Medical - Instruments & Supplies

Employees (FY): 13000

Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.

shop
Company facts
Brenton L. Saunders
CEO
13000
Employees worldwide
shop
Performance
16.24%
Last 12 months
-9.8%
Last 5 years
shop
Growth
$5.10B
Revenue year
$-352,000,000
Net income
shop
Valuation
$6.44B
Market Cap
-16.75
Price/Earnings Ratio

Stocks related to Bausch + Lomb Corporation

Selected based on industry alignment and relative market positioning.

ATR
AptarGroup, Inc.
127.41
-0.70%
3.6
Sell
Buy
AptarGroup, Inc.
RGEN
Repligen Corporation
167.60
-1.19%
5.7
Sell
Buy
Repligen Corporation
AVTR
Avantor, Inc.
14.97
-1.45%
7.2
Sell
Buy
Avantor, Inc.
TFX
Teleflex Incorporated
138.36
-1.14%
3.6
Sell
Buy
Teleflex Incorporated
STVN
Stevanato Group S.p.A.
20.51
-0.15%
5.9
Sell
Buy
Stevanato Group S.p.A.

Events and news impacting Bausch + Lomb Corporation stock

Earnings, coporate decisions and industry developments that can affect the share price.

Bausch + Lomb Corporation fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.